Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd.
Colospan Ltd. ("Colospan") provides Galmed Pharmaceuticals Ltd.
PRNewsWire6/22/2026Neutral
GLMD
Galmed Pharmaceuticals LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$4.37M
P/E Ratio
—
EPS
$-2.40
Beta
0.74
52W High
$2.34
52W Low
$0.41
50-Day MA
$0.60
200-Day MA
$0.85
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapies for the treatment of liver diseases. The company is headquartered in Tel Aviv, Israel.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-8.43M |
| Operating Margin | 0.00% |
| Return on Equity | -64.20% |
| Return on Assets | -28.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.40 |
| Price-to-Book | 0.28 |
| Price-to-Sales (TTM) | 61.38 |
| EV/Revenue | 6.09 |
| EV/EBITDA | 0.32 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $7.68M |
| Float | $6.37M |
| % Insiders | 3.30% |
| % Institutions | 1.92% |
Historical Volatility
HV 10-Day
108.94%
HV 20-Day
102.95%
HV 30-Day
154.54%
HV 60-Day
119.96%
HV Rank
99.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($12.00 target)
1
HoldLatest News
Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis
- Tissue Dynamics identified a previously unrecognized metabolic mechanism driving cardiac fibrosis using a human cardiac organoid model, revealing disease biology that is not accessible through conventional animal models. - In inflammatory human cardiac organoids, the combination of Aramchol Meglumine and a selective PPARα agonist reduced fibrotic burden by approximately 4-fold (p
PRNewsWire6/2/2026Neutral
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg
Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling: Production of GMP clinical batch for Galmed's upcoming clinical trials Solidification and prolongation of Aramchol's IP protection Potential reduction in drug CoGs by ~50% Improvement in patients' convenience and compliance upon potential commercialization RAMAT-GAN, Israel, May 14, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, announced today major milestone results from a Phase 1 PK study in healthy subjects (Study AM-001).
PRNewsWire5/14/2026Neutral
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
Novel vascularized, sensor-embedded cardiac organoid model will focus on chronic post-MI remodeling and HFpEF, linking lipid metabolism, SCD1 activity, fibrosis, and impaired tissue repair REHOVOT, Israel and RAMAT-GAN, Israel, May 6, 2026 /PRNewswire/ -- Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd.
PRNewsWire5/6/2026Neutral
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
Recently, Galmed announced breakthrough medicinal chemistry work converting Aramchol into a brain-penetrant SCD1 inhibitor, potentially positioning Aramchol as a first-in-class therapy for synucleinopathies and other CNS diseases. Among CNS unmet conditions, brain metastasis (BM) remains a lethal progression of the primary cancer in urgent need of novel and effective therapies.
PRNewsWire4/14/2026Neutral
More HEALTHCARE Stocks
Data last updated: 7/9/2026